Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Highlights Symbyax Onset Of Action; Other Bipolar Presentations At APA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly is highlighting a rapid onset of action and lack of treatment-emergent mania for its olanzapine/fluoxetine combination Symbyax, currently pending at FDA for the treatment of bipolar depression.

Related Content

Zyprexa and Seroquel add bipolar claims
Lilly Symbyax complete response
Antipsychotics & Diabetes: Pfizer Highlighting Differences Between Drugs
GSK Lamictal Bipolar Claim "Approvable"; Exact Indication Under Discussion





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts